These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29147875)

  • 1. Evaluation of NfsA-like nitroreductases from Neisseria meningitidis and Bartonella henselae for enzyme-prodrug therapy, targeted cellular ablation, and dinitrotoluene bioremediation.
    Rich MH; Sharrock AV; Hall KR; Ackerley DF; MacKichan JK
    Biotechnol Lett; 2018 Feb; 40(2):359-367. PubMed ID: 29147875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cofactor consumption screen identifies promising NfsB family nitroreductases for dinitrotoluene remediation.
    Williams EM; Sharrock AV; Rylott EL; Bruce NC; MacKichan JK; Ackerley DF
    Biotechnol Lett; 2019 Oct; 41(10):1155-1162. PubMed ID: 31392514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.
    Vass SO; Jarrom D; Wilson WR; Hyde EI; Searle PF
    Br J Cancer; 2009 Jun; 100(12):1903-11. PubMed ID: 19455141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.
    Prosser GA; Copp JN; Syddall SP; Williams EM; Smaill JB; Wilson WR; Patterson AV; Ackerley DF
    Biochem Pharmacol; 2010 Mar; 79(5):678-87. PubMed ID: 19852945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.
    Prosser GA; Copp JN; Mowday AM; Guise CP; Syddall SP; Williams EM; Horvat CN; Swe PM; Ashoorzadeh A; Denny WA; Smaill JB; Patterson AV; Ackerley DF
    Biochem Pharmacol; 2013 Apr; 85(8):1091-103. PubMed ID: 23399641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy.
    Chan-Hyams JVE; Copp JN; Smaill JB; Patterson AV; Ackerley DF
    Biochem Pharmacol; 2018 Dec; 158():192-200. PubMed ID: 30352235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering the
    Sharrock AV; McManaway SP; Rich MH; Mumm JS; Hermans IF; Tercel M; Pruijn FB; Ackerley DF
    Front Pharmacol; 2021; 12():701456. PubMed ID: 34163368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954.
    Jarrom D; Jaberipour M; Guise CP; Daff S; White SA; Searle PF; Hyde EI
    Biochemistry; 2009 Aug; 48(32):7665-72. PubMed ID: 19580253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy.
    Green LK; Syddall SP; Carlin KM; Bell GD; Guise CP; Mowday AM; Hay MP; Smaill JB; Patterson AV; Ackerley DF
    Mol Cancer; 2013 Jun; 12():58. PubMed ID: 23758947
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Mowday AM; Copp JN; Syddall SP; Dubois LJ; Wang J; Lieuwes NG; Biemans R; Ashoorzadeh A; Abbattista MR; Williams EM; Guise CP; Lambin P; Ackerley DF; Smaill JB; Theys J; Patterson AV
    Theranostics; 2020; 10(23):10548-10562. PubMed ID: 32929365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering
    Williams EM; Rich MH; Mowday AM; Ashoorzadeh A; Copp JN; Guise CP; Anderson RF; Flanagan JU; Smaill JB; Patterson AV; Ackerley DF
    Biochemistry; 2019 Sep; 58(35):3700-3710. PubMed ID: 31403283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel nitroreductases from Bacillus cereus and their interaction with the CB1954 prodrug.
    Gwenin VV; Poornima P; Halliwell J; Ball P; Robinson G; Gwenin CD
    Biochem Pharmacol; 2015 Dec; 98(3):392-402. PubMed ID: 26415543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitroreductase from Bacillus licheniformis: a stable enzyme for prodrug activation.
    Emptage CD; Knox RJ; Danson MJ; Hough DW
    Biochem Pharmacol; 2009 Jan; 77(1):21-9. PubMed ID: 18840409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623.
    Sharrock AV; Mumm JS; Williams EM; Čėnas N; Smaill JB; Patterson AV; Ackerley DF; Bagdžiūnas G; Arcus VL
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy.
    Green LK; Storey MA; Williams EM; Patterson AV; Smaill JB; Copp JN; Ackerley DF
    Cancers (Basel); 2013 Aug; 5(3):985-97. PubMed ID: 24202330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxygen-insensitive nitroreductase E. coli NfsA, but not NfsB, is inhibited by fumarate.
    Day MA; Jarrom D; Rajah N; Searle PF; Hyde EI; White SA
    Proteins; 2023 May; 91(5):585-592. PubMed ID: 36443029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility.
    Williams EM; Little RF; Mowday AM; Rich MH; Chan-Hyams JV; Copp JN; Smaill JB; Patterson AV; Ackerley DF
    Biochem J; 2015 Oct; 471(2):131-53. PubMed ID: 26431849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxygen-insensitive nitroreductases: analysis of the roles of nfsA and nfsB in development of resistance to 5-nitrofuran derivatives in Escherichia coli.
    Whiteway J; Koziarz P; Veall J; Sandhu N; Kumar P; Hoecher B; Lambert IB
    J Bacteriol; 1998 Nov; 180(21):5529-39. PubMed ID: 9791100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954.
    Prosser GA; Patterson AV; Ackerley DF
    J Biotechnol; 2010 Oct; 150(1):190-4. PubMed ID: 20727918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time dependent HPLC analysis of the product ratio of enzymatically reduced prodrug CB1954 by a modified and immobilised nitroreductase.
    Ball P; Thompson E; Anderson S; Gwenin V; Gwenin C
    Eur J Pharm Sci; 2019 Jan; 127():217-224. PubMed ID: 30414836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.